At Pursuit of Hope, we fight for those who are suffering. We are committed to expanding access to effective substance abuse disorder treatment worldwide to save lives, and to provide hope for people suffering from substance abuse disorders by helping them achieve the lives they want and deserve. We’re fighting every minute of every day to achieve this vision by your partner for living a successful and healthier life!
During our effort to expand access to opioid agonist therapy beyond traditional opioid agonist therapy programs, Congress made an amendment to the Drug Addiction Treatment Act (DATA 2000), signed in 2002, which allows qualified physicians to prescribe and dispense approved buprenorphine (Subutex) and buprenorphine/naloxone (Suboxone) sublingual tablets (hereafter collectively termed buprenorphine) in office-based practices.
In 2003, after an evidence-based literature review and consultation with topic experts, the VHA established non-formulary guidelines for buprenorphine use, and in 2006, formulary guidelines were established. This permitted the use of buprenorphine sublingual tablets for the treatment of opioid dependence in practices such as Pursuit of Hope.
Buprenorphine has been shown to be a safe and effective treatment of opioid dependence in non-specialized, outpatient, office-based settings. We have encouraged opioid-dependent patients who would not otherwise present themselves to an opioid-assisted treatment program (OATP) to have access to such treatment.